Mateusz M.
- Country
- Poland
- Department
- n/a
Research Overview
- Evaluation of Obicetrapib on Major Adverse Cardiovascular Events in Atherosclerotic Cardiovascular Disease Patients on Maximal Lipid-Modifying Therapy
- A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active-Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation
- ZENITH: A Phase 3 Global, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Zilebesiran in Addition to Standard of Care in Reducing Major Adverse Cardiovascular Events in Adult Patients with Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease
Data & Insights
Has run more than one trial at 202 of 781 partner sites.
Specializations
Cardiovascular Medicine
Specializes in investigating therapeutic approaches for atrial fibrillation and its associated complications, with particular emphasis on preventing cardioembolic events.
- Stroke Prevention
- Systemic Embolism Management
- Cardiac Rhythm Disorders
Explores innovative anticoagulation strategies in cardiac care.
Thrombosis Research
Focuses on evaluating novel therapeutic agents for thromboembolic prevention in patients with cardiac conditions.
- Anticoagulation Therapy
- Embolic Risk Assessment
- Cardiovascular Prevention
Investigates comparative effectiveness of anticoagulant medications.
Clinical Cardiology
Conducts research in cardiac arrhythmia management and prevention of associated complications.
- Arrhythmia Treatment
- Cardiovascular Risk Management
- Prevention Medicine
Studies advanced therapeutic options for cardiac rhythm disorders.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.